Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q1 2025 U.S. Biopharma Recap

On Groundhog Day 2025, Punxsutawney Phil saw his shadow and, as per tradition, predicted six more weeks of winter. That proved apropos of biopharma’s performance in the first quarter of 2025, as the sector finds itself reliving existential anxieties. The XBI and NBI retreated 22% and 13%, respectively, from their November 2024 highs as recession fears loom and the market navigates large disruptions at the FDA and HHS. The IPO window showed brief signs of life with five pricings in January and early February while secondary activity slowed with total proceeds down 76% and deal volume down 70% compared to Q1 2024. Private financings proved a lone bright spot in financing markets, underscored by several Series A mega-rounds, although crossover activity slowed compared to previous quarters.

Dealmaking remained anemic, with Intra-Cellular/J&J the only sizable public M&A transaction. Meaningful M&A (>$1 billion in deal value) stayed concentrated on the private side, accounting for over 75% of these larger transactions. Amid this tumultuous backdrop, our recent conversations with biopharma investors highlight renewed caution, as they are caught between a heightened focus on commercially viable drugs and supporting continued scientific innovation.

The second quarter should provide the market with greater clarity on President Trump’s policies and tariff agenda, while expectations for additional rate cuts from the Fed may provide a shot in the arm for a resilient biopharma sector.

William Blair's biopharma team shares additional perspectives on the biopharma environment and what to expect for the remainder of 2025.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Abry Partners and CAPZA Have Agreed to Make a Strategic Minority Investment in European Dynamics

    William Blair acted as the exclusive financial advisor to Abry Partners in connection with its pending significant minority investment in European Dynamics, alongside CAPZA.

    Read more
  • William Blair Adds Secondaries Lead in Europe

    William Blair announced today the continued growth of the firm’s Private Capital Advisory team in Europe with the addition of Tim-Oliver Seidel.

    Read more
  • William Blair Private Capital Advisory: 2025 Secondary Market Report

    After an exceptional 2024—with global secondary volume growing approximately 40% from 2023—market insiders remain bullish and expect $175 billion in global transaction volume this year.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures